Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Prednisolone
Drug ID BADD_D01831
Description Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status approved; vet_approved
ATC Code A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB00860
KEGG ID D00472
MeSH ID D011239
PubChem ID 5755
TTD Drug ID D0D1SG
NDC Product Code 38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII 9PHQ9Y1OLM
Synonyms Prednisolone | Predate | Predonine | Di-Adreson-F | Di Adreson F | DiAdresonF
Chemical Information
Molecular Formula C21H28O5
CAS Registry Number 50-24-8
SMILES CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neurosarcoidosis17.06.01.005; 10.02.06.0050.000035%Not Available
No reaction on previous exposure to drug08.06.01.0420.000035%Not Available
Omental infarction24.04.08.023; 07.15.02.0170.000035%Not Available
Organic brain syndrome19.07.03.0110.000035%Not Available
Pancreatic failure07.18.02.0110.000052%Not Available
Penetrating aortic ulcer24.02.03.0070.000035%Not Available
Penetrating atherosclerotic ulcer24.03.04.0160.000035%Not Available
Periorbital swelling23.04.01.025; 10.01.05.025; 06.08.03.0320.000035%Not Available
Pharyngeal swelling22.04.05.0280.000052%Not Available
Pleural adhesion22.05.03.0050.000035%Not Available
Pleuroperitoneal communication22.05.02.012; 12.02.18.003; 07.07.01.0170.000052%Not Available
Polychondritis15.07.03.010; 10.04.04.0310.000052%Not Available
Polyglandular autoimmune syndrome type III05.09.02.003; 10.04.08.0030.000070%Not Available
Primary adrenal insufficiency14.11.01.056; 05.01.02.0120.000052%Not Available
Rectosigmoid cancer16.13.01.024; 07.21.01.0230.000035%Not Available
Retinal drusen06.09.03.0340.000315%Not Available
Sebaceous glands overactivity23.02.07.0080.000035%Not Available
Sensory processing disorder19.22.02.005; 17.02.03.0250.000035%Not Available
Serous retinal detachment06.09.03.0370.000087%Not Available
Sinus pain22.12.03.0230.000035%
Skin weeping23.03.03.1010.000035%Not Available
Squamous cell carcinoma of the vagina21.08.03.008; 16.12.09.0010.000052%Not Available
Steroid dependence08.06.01.0470.000077%Not Available
Steroid diabetes14.06.01.019; 05.06.01.0190.000699%Not Available
Still's disease10.02.07.002; 08.05.02.017; 15.01.03.0070.000087%Not Available
Swelling of eyelid23.04.01.026; 10.01.05.026; 06.04.04.0180.000035%Not Available
Therapeutic product effect incomplete08.06.01.0520.000584%Not Available
Therapeutic response changed08.06.01.0590.000077%Not Available
Therapy non-responder08.06.01.0630.000619%Not Available
Therapy partial responder08.06.01.0640.000087%Not Available
The 35th Page    First    Pre   35 36    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene